Nanion Corporate Blog

 

03.08.2020: Free Application Note - NaV1.5-ΔKPQ late INa current properties and pharmacology

Activation and inactivation of peak currents of NaV1.5-ΔKPQ

What you will learn:

  • Peak and late INa could be reliably recorded from NaV1.5-ΔKPQ expressing HEK cells without pharmacological enhancement; which could potentially interact with test compounds.
  • Late INa from NaV1.5-ΔKPQ was more potently inhibited by ranolazine and mexiletine than peak NaV1.5-ΔKPQ or WT peak currents.
  • Using the SyncroPatch 384i automated patch clamp system in combination with the NaV1.5-ΔKPQ cell line provided a reliable high throughput CiPA-compliant cardiac safety screening assay without the need for openers such as ATX-II.

Download the Application Note

Back to Overview

 

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.